Curis Lifesciences IPO Listing at 14.14% premium at ₹146 Per Share

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Fri Nov 14 2025

Curis Lifesciences IPO Listing at 14.14% premium at ₹146 Per Share

Click and Sign Up to Get Latest Updates on Curis Lifesciences Limited

Table of Contents

Curis Lifesciences IPO Listing:

On the NSE SME platform, shares are listed at ₹146 per share, reflecting a premium of 14.14% against the issue price of 128 per share.

Curis Lifesciences IPO Subscription Status

The Curis Lifesciences IPO was subscribed 74.39 times at the close of the bidding. In this subscription, qualified institutional buyers (QIBs) received 96.17 times the allocation, and non-institutional investors (NIIs) received 115.46 times the allocation. The retail quota of the issue was subscribed to 33.30%.

Curis Lifesciences IPO: Check Key Details

The issue is entirely a fresh issue of 22,00,000 shares. The IPO is expected to be listed on the NSE and SME with a tentative listing date of 14th November 2025. The Curis Lifesciences IPO is expected to take place from 7th November 2025 to 11th November 2025. The face value of Curis Lifesciences IPO shares is ₹2 per share, and the IPO price is set at ₹120 to ₹128 per share.

IPO Open Date	7th November 2025
IPO Close Date	11th November 2025
IPO Allotment Date	12th November 2025
Refund Initiation	13th November 2025
Face Value	₹10 per share
Price Band	₹120 to ₹128 per share
Lot Size	1,000 Shares
Issue Size	21,50,000 shares(aggregating up to ₹27.52 Cr)
Issue Type	Bookbuilding IPO
Listing At	NSE and SME
Listing Date	14th November 2025

About Curis Lifesciences Limited

Curis Lifesciences Limited was established in 2010 and is a prominent pharmaceutical company that engages in the development, manufacturing, and distribution of various products. It has manufacturing units globally and domestically, through licenses and on a contract basis, and it has its own brand marketing.

Experienced Promoters and Management Team
Wide range of Products
Strategic Location of Manufacturing Facility
Scalable Business Model
Quality assurance

Curis Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Curis Lifesciences Limited’s IPO. Look at the table to learn about Curis Lifesciences Limited’s financials.

Year Ended	31th July 2025	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	56.29	42.53	33.88	29.75
Revenue	19.51	49.65	35.87	36.42
Profit After Tax	2.87	6.11	487	1.88
EBITDA	4.24	9.54	8.39	3.28
Net Worth	19.10	16.23	5.87	1.01
Reserve and Surplus	13.16	10.29	5.37	0.51
Total Borrowing	15.32	15.62	17.09	16.19

Explanation

Curis Lifesciences Limited’s revenue increased by 38% from ₹4.87 crores in March 2024 to ₹49.65 crores in March 2025. Moreover, the company’s PAT increased by 25% from ₹4.87 crores to ₹6.11 crores. Investors can analyse other relevant factors and make a decision accordingly.

Objectives of the Curis Lifesciences IPO

The primary objective of the Curis Lifesciences IPO is to raise ₹27.52 crore. However, before applying for the IPO, you should be aware of its secondary objectives. Explore them below

Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities.
Capital Expenditure towards Construction of a Storage Facility
Pre-payment/Repayment of outstanding Secured Loans
Product Registrations in other countries
Funding our Working Capital Requirements
General Corporate Purposes

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!